First Trust Advisors LP Acquires Shares of 500,273 OPKO Health, Inc. $OPK

First Trust Advisors LP acquired a new position in shares of OPKO Health, Inc. (NASDAQ:OPK) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 500,273 shares of the biotechnology company’s stock, valued at approximately $570,000.

Several other institutional investors have also recently made changes to their positions in OPK. Geode Capital Management LLC boosted its holdings in OPKO Health by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 11,061,318 shares of the biotechnology company’s stock worth $13,940,000 after purchasing an additional 67,973 shares during the last quarter. Millennium Management LLC increased its stake in OPKO Health by 39.2% in the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after buying an additional 1,798,385 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in OPKO Health by 150.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock valued at $7,544,000 after buying an additional 3,600,378 shares during the last quarter. UBS Group AG lifted its position in shares of OPKO Health by 12.1% during the 4th quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company’s stock worth $6,745,000 after buying an additional 577,248 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in shares of OPKO Health by 466.7% in the 1st quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock worth $2,671,000 after buying an additional 1,324,988 shares during the last quarter. Institutional investors own 64.63% of the company’s stock.

Wall Street Analysts Forecast Growth

OPK has been the subject of several recent analyst reports. Barrington Research lowered OPKO Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 29th. Weiss Ratings raised OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Wall Street Zen raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Finally, HC Wainwright reiterated a “buy” rating on shares of OPKO Health in a research note on Wednesday, July 29th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $1.55.

OPKO Health Stock Performance

Shares of OPK opened at $1.39 on Wednesday. OPKO Health, Inc. has a fifty-two week low of $0.98 and a fifty-two week high of $1.73. The business has a 50-day moving average of $1.38 and a 200 day moving average of $1.27. The firm has a market cap of $1.04 billion, a P/E ratio of -15.44 and a beta of 1.51. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.93 and a current ratio of 3.35.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings data on Monday, July 27th. The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.07. The business had revenue of $163.58 million for the quarter, compared to the consensus estimate of $131.23 million. OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.88%. The company’s revenue was up 4.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.19) earnings per share. As a group, research analysts forecast that OPKO Health, Inc. will post -0.24 EPS for the current year.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.